BFA Law Investigates ADMA Biologics After 29% Stock Plunge

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: 1 day ago

0mins

ADMA-1.53%

Should l Buy ADMA?

Source: Newsfilter

Stock Price Plunge: ADMA Biologics' stock plummeted 29% over two trading days, dropping from $13.59 to $9.63 per share, primarily due to a report from Culper Research alleging that the company engaged in channel stuffing to falsely report a 20% revenue growth for 2025, severely undermining investor confidence.
Investigation Context: BFA Law is investigating potential violations of federal securities laws by ADMA Biologics, particularly regarding the authenticity of its reported revenue growth, which, if substantiated, could lead to legal repercussions that may impact the company's future financing and market reputation.
Channel Stuffing Allegations: The report from Culper Research claims that ADMA induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allegedly allowed the company to inflate revenue figures; without this scheme, a projected 3% revenue decline for 2025 would have occurred, posing a serious threat to the company's financial health.
Legal Implications: Investors are encouraged to contact BFA Law for more information, as they may have the opportunity to participate in a class action lawsuit, which could lead to compensation for affected investors, further impacting ADMA's shareholder structure and market performance.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ADMA

About ADMA

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

ADMA Biologics Under Investigation for Securities Fraud

1 hour agoGlobenewswire

Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential securities fraud, as the reported 20% revenue growth in 2025 may have been artificially inflated through channel stuffing, indicating serious issues with the company's financial transparency.
Revenue Manipulation Allegations: According to a report by Culper Research, ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allowed the company to inflate revenue figures; without this scheme, actual revenue would have declined by 3% in 2025, significantly undermining investor confidence.
Stock Price Plunge: The news of the investigation caused ADMA Biologics' stock to drop 29% over two trading days, from $13.59 per share on March 23 to $9.63 per share on March 25, reflecting market concerns regarding the company's financial health and credibility.
Legal Implications: Investors are encouraged to submit their information for legal assistance, with BFA offering representation on a contingency basis, demonstrating the firm's proactive approach to addressing potential legal liabilities and protecting shareholder interests.

US Stocks Performance Review and Outlook

12 hours agoCNBC

Employment Data Expectations: ADP is set to release employment data at 8:15 a.m. ET, with a consensus estimate of 39,000 new jobs in the private sector, which will provide a crucial indicator of economic health and could influence investor confidence and market trends.
Retail Sales Growth: Retail sales figures are expected to be released at 8:30 a.m., with a general forecast of a 0.5% increase, a data point that will directly impact consumer spending and the outlook for economic recovery, potentially guiding a market rebound.
Corporate Earnings Dynamics: Cal-Maine, Conagra, and Lamb Weston are scheduled to report earnings before the bell, with Cal-Maine's stock flat over the past three months, Conagra down 9%, and Lamb Weston showing no significant change, all of which will affect investor sentiment towards the food sector.
Market Performance Review: In the first quarter, the Russell 2000 index rose by 0.58%, making it the best performer among major indices, while the S&P 500 and Nasdaq 100 fell by 4.63% and 5.98%, respectively, reflecting market volatility and cautious investor sentiment.

Pomerantz LLP Investigates ADMA Biologics for Securities Fraud

13 hours agoGlobenewswire

Securities Fraud Investigation: Pomerantz LLP is investigating whether ADMA Biologics has engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and seek legal remedies.
Short Report Allegations: On March 24, 2026, Culper Research published a short report alleging that ADMA's reported growth is fictional, estimating a 3% revenue decline in 2025 when excluding channel stuffing, contrary to the reported 20% growth.
Stock Price Plunge: Following the release of the short report, ADMA's stock price fell by $2.26, a 16.63% drop, closing at $11.33 per share, indicating market concerns regarding the company's financial health.
Legal Action Outlook: Pomerantz LLP, recognized for its success in securities class action lawsuits, may provide legal support for affected investors seeking compensation, leveraging its extensive experience in this field.

ADMA Biologics Under Investigation for Securities Violations

13 hours agoGlobenewswire

Investigation Launched: Kirby McInerney LLP is investigating ADMA Biologics for potential violations of federal securities laws by senior management, indicating significant legal risks that could undermine investor confidence.
Allegations Reported: A report from Culper Research alleges ADMA engaged in 'channel stuffing' by incentivizing distributors to stockpile ASCENIV through rebates and extended payment terms, raising concerns about the company's financial transparency and integrity.
Stock Price Decline: Following the investigation announcement, ADMA's stock price plummeted from $13.59 on March 23 to $11.33 on March 24, marking a 17% drop that reflects market apprehension regarding the company's future prospects.
Legal Implications: Although no lawsuit has been filed yet, the ongoing investigation could lead to future legal actions, prompting investors to remain vigilant about their rights and potential compensation issues.